To the Editor-There has been a flurry of hand wringing in recent years by the Infectious Diseases Society of America (IDSA) and other responsible organizations about the emerging "crisis" of antibiotic resistance [1] . This is surprising, because even before the discovery of the sulfonamides in 1935 and the introduction of penicillin in 1941, there was substantial evidence that antimicrobial resistance would become a major problem. Charles Darwin anticipated the survival of the fittest microbes in 1859 in On the Origin of Species by Natural Selection [2] . In his 1908 Nobel lecture, Paul Ehrlich, the father of chemotherapy, described trypanosomes that became multiply resistant to arsenicals and observed the emergence of resistance during therapy. In his 1945 Nobel lecture, Alexander Fleming warned about development of resistance that could result from the over-the-counter purchase of penicillin. In the 1950s, Ernest Jawetz and Maxwell Finland warned about the overzealous promotion of antibiotics and the potential for developing antibiotic resistance [3, 4] . In the 1970s, I and others reported that, in approximately one-half of cases in which antibiotics were used in hospitals, they were used inappropriately because of an incorrect choice of antibiotic, dose, or duration of treatment [5] ; the US Veterans Administration published audit guidelines for the use of antibiotics [6] ; and the National Institutes of Health held a symposium on the problems of antibiotic use [7] .
In the 1980s, The Alliance for Prudent Use of Antibiotics was formed. The Fogarty Center of the National Institutes of Health established task forces to examine the worldwide problems of antibiotic use and resistance [8] .
The membership of the IDSA was asked more than 20 years ago to take the responsibility of dealing with this problem [9] . The first IDSA guidelines to improve the use of antimicrobial agents in hospitals were published in 1988 [10] . The leadership of the IDSA considered these recommendations to be quixotic. All of these reports were ignored and forgotten, because the leading opinion makers, supported by the pharmaceutical industry, argued that the discovery of new antibiotics would overcome the problem of resistance. They were not interested in "antibiotic stewardship." The current IDSA leadership continues to pursue this agenda by proposing questionable incentives to reinvigorate pharmaceutical investment. I do not question their sincerity, but they do have numerous potential conflicts of interest [1] .
The World Health Organization [11] and the Centers for Disease Control and Prevention, after some prodding by the US Congress [12] , have developed rational public health plans to combat antimicrobial resistance. We should follow their advice. We need to be aware, however, that the emphasis on surveillance of antibiotic resistance can be a double-edged sword. On the one hand, it is essential to help guide therapy. On the other hand, it can be used as a powerful marketing tool to influence inappropriate use of new drugs that need to be reserved for the treatment of severe infections.
The "old" literature is rarely if ever referenced by the "new generation" of experts. George Santayana's famous statement that "Those who cannot remember the past are condemned to repeat it" is as true as ever [13, p. 284] . Thank goodness that the message has finally gotten through. The torch has been passed to a new generation. We can only hope that it is not too late.
Reply to Kunin: Rationale for Antibiotic Development Incentives
To the Editor-We appreciate the thoughtful comments of Dr. Kunin and all of his efforts through the years to promote the proper use of antibiotics [1] . We would like to respond with several points. Dr. Kunin reminds us that the Infectious Diseases Society of America (IDSA) has been addressing the problem of antimicrobial resistance for over 40 years. In combination with the National Institutes of Health, the Centers for Disease Control and Prevention, the US Department of Veterans Affairs, and the World Health Organization, extensive efforts have been made to avert the problem of microbial resistance as much as possible. These efforts have been primarily through surveillance, attempts by the IDSA to promote "antibiotic stewardship," direct interaction with legislators, scholarly publications regarding concerns about antibiotic resistance, and consultations with regulatory agencies on clinical research design. The recent IDSA Public Policy Commentary [2] stresses how these efforts have had limited success to date, considering that the level of antimicrobial resistance is now greater than it has been in the history of anti-infective agents and that we are witnessing a dramatic egress of the major pharmaceutical companies from the development of newer anti-infectives. The promotion of "antibiotic stewardship" is a critical role for the IDSA, and considerable efforts are ongoing. This guidance [3] is just one example of multiple current efforts. However, the IDSA is an organization of ∼9000 professionals and currently has no regulatory authority for "antibiotic stewardship" for the 11,000,000 licensed physicians and health care workers who are entitled to use antibiotics in any way that they feel is appropriate. The complex problem that these unregulated physicians and health care workers face is that of being asked to place a subset of their patients at risk for mortality due to curable infectious diseases by either withholding antibiotics or shortening the course of therapy. In addition, unlike in many other countries, they are asked to take this potentially high-risk, conservative medical approach in a nation in which medical law suits are frequent and risk avoidance strategies are highly valued by the general population. Against this background of biologically inevitable antimicrobial resistance, the failure of previous strategies to minimize microbial resistance development, the lack of significant antiinfective development through federal government agencies, and the egress of the major pharmaceutical companies from anti-infective development, the IDSA, after considerable research involving the top executives in the pharmaceutical industry, has suggested the financial incentives as described in its commentary [2] as an ad-
